Seems like the Trump administration plans to push ahead with negotiating drug prices under the Inflation Reduction Act! 💊🩺📊

A glimmer of positive news among a sea of mayhem this week.

www.cms.gov/newsroom/pre...

🚨New @portalresearch.org paper🚨 in JAMA Health Forum.

HIGHLIGHTS:
🔵 Biosimilars made up <2% of adalimumab use in 2023.
🔵 Net prices dropped by >40%...but the Humira list price increased.

Meaning: Abbvie payed confidential rebates to maintain Humira dominance. 💊🩺📊

📜 jamanetwork.com/journals/jam...

Just got a cold call from a group called "Voters for Cures" asking me to lobby Congress to pass PBM reform.

No surprise who's funding that campaign. 🙄

We absolutely need PBM regulation. But I hope Congress makes sensible reforms that don't ultimately raise prices by manufacturers. #Healthpolicy

Earlier this year, Catherine Hwang, @akesselheim.bsky.social, and I argued that Medicare should cover anti-obesity medications...if they could negotiate fair prices.

Is today's news a missed policy opportunity???

www.cambridge.org/core/journal...

#Healthpolicy @portalresearch.org

And for more detail, check out the Perspective article by me, @akesselheim.bsky.social, and @wbfeldman.bsky.social.

www.nejm.org/doi/full/10....

How can clinicians help their patients afford costly medications?? 💊💰

In a recent JAMA review, we outlined an algorithm and talk about the pros and cons of several options, including copay cards, pharmacy coupons, and more.

#Medsky 🩺📊
@portalresearch.bsky.social

jamanetwork.com/journals/jam...

I live for being congratulated by my EHR. Happy Thanksgiving, all!

Net prices for weight loss GLP1s will come down now that there’s competition between Novo & Lilly.

But competition isn’t an on/off switch. A duopoly is only marginally better than a monopoly.

E.g. 3+ generics are needed to see real price reductions. www.nejm.org/doi/10.1056/... #healthpolicy

Want to know what PBM reforms Congress is considering?

BWH resident Chris Cai and I have got you covered in a new #NEJM perspective.

www.nejm.org/doi/full/10....

#healthpolicy

The real question here is why are we paying so much for Eylea and Lucentis when Avastin is so much less expensive.

@statnews.bsky.social #healthpolicy

www.statnews.com/pharmalot/20...

Hmm… community oncology practices have profited by selling expensive drugs for years. And we’re supposed to feel bad that drug prices will go down because of the #IRA?? 🤔

Seems like a #healthpolicy win, not a consequence.

jamanetwork.com/journals/jam...